Martinez-Ruzafa I, Dominguez P A, Dervisis N G, Sarbu L, Newman R G, Cadile C D, Kitchell B E
Department of Small Animal Clinical Sciences, Center for Comparative Oncology, College of Veterinary Medicine, Michigan State University, East Lansing, MI 48824-1314, USA.
J Vet Intern Med. 2009 May-Jun;23(3):570-7. doi: 10.1111/j.1939-1676.2009.0279.x. Epub 2009 Mar 9.
This study was performed to determine the toxicity of gemcitabine-carboplatin doublet therapy in cats with carcinomas.
Gemcitabine and carboplatin are safe in tumor-bearing cats.
Twenty cats with spontaneously occurring carcinomas.
A cohort of 6 cats received gemcitabine (2 mg/kg IV) on days 1, 8, and 15 and carboplatin (10 mg/kg IV) immediately after gemcitabine on day 1 of a 21-day cycle. A 2nd cohort of 14 cats received carboplatin 4 hours after gemcitabine on day 1 and gemcitabine on day 8 but not day 15. The cycles were repeated every 21 days.
Cats in the 1st cohort received a median of 3.75 cycles per animal (range, 1-6). Two cats (33.3%) developed grade 3 or 4 neutropenia, 1 (16.7%) grade 4 thrombocytopenia, and 1 (16.7%) grade 3 gastrointestinal toxicity. Gemcitabine dose reductions and treatment delays occurred in 1 and 4 cats, respectively. Cats in the 2nd cohort received a median of 2 cycles per animal (range, 0.5-10). Two cats (14.3%) had grade 3 or 4 neutropenia and 1 (7.1%) had grade 3 and 4 gastrointestinal toxicity. One cat required gemcitabine dose reduction and 6 had treatment delays. In the 2nd cohort, of 11 cats with measurable tumors, there was 1 complete response (pancreatic carcinoma) and 1 partial response (squamous cell carcinoma, receiving concurrent nonsteroidal anti-inflammatory drugs).
Gemcitabine-carboplatin combination appears moderately well tolerated in tumor-bearing cats. Minimal patient benefit suggests that alternative schedules or combinations of gemcitabine with other agents should be explored.
本研究旨在确定吉西他滨-卡铂联合疗法对患癌猫的毒性。
吉西他滨和卡铂对荷瘤猫是安全的。
20只自发患癌的猫。
一组6只猫在21天周期的第1天、第8天和第15天接受吉西他滨（2mg/kg静脉注射），并在第1天吉西他滨注射后立即接受卡铂（10mg/kg静脉注射）。另一组14只猫在第1天吉西他滨注射4小时后接受卡铂，第8天接受吉西他滨，但第15天不接受。每21天重复一个周期。
第一组猫每只动物接受的周期中位数为3.75个（范围1 - 6个）。2只猫（33.3%）出现3级或4级中性粒细胞减少，1只（16.7%）出现4级血小板减少，1只（16.7%）出现3级胃肠道毒性。分别有1只和4只猫出现吉西他滨剂量减少和治疗延迟。第二组猫每只动物接受的周期中位数为2个（范围0.5 - 10个）。2只猫（14.3%）出现3级或4级中性粒细胞减少，1只（7.1%）出现3级和4级胃肠道毒性。1只猫需要减少吉西他滨剂量，6只出现治疗延迟。在第二组中，11只可测量肿瘤的猫中有1只完全缓解（胰腺癌），1只部分缓解（鳞状细胞癌，同时接受非甾体抗炎药）。
吉西他滨-卡铂联合疗法在荷瘤猫中似乎耐受性中等良好。患者获益极小，提示应探索吉西他滨的其他给药方案或与其他药物的联合方案。
